Yauheni V. Baranau
Minsk, HM, Belarus
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: November 04, 2025
Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis.
Journal: Research square
Published: November 28, 2024
Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: the FLINTER study.
Journal: Therapeutic advances in medical oncology
Published: July 09, 2024
Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial.
Journal: Frontiers in oncology
Published: November 22, 2023
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 19, 2023
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Journal: Breast cancer research and treatment
Published: March 08, 2021
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Journal: Cancer chemotherapy and pharmacology
Published: July 12, 2019
Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
Journal: Expert review of anticancer therapy
Published: March 28, 2018
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Journal: The Lancet. Oncology
Published: April 13, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026